LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | HG-6-64-01 | 3.33 | uM | LJP6 | 72 | hr | 868 | 1045 | 3556 | 0.2933 | 0.0918 |
MDA-MB-231 | HG-6-64-01 | 10 | uM | LJP6 | 72 | hr | 868 | 526 | 3556 | 0.1482 | -0.2197 |
MDA-MB-231 | Neratinib | 0.04 | uM | LJP5 | 72 | hr | 868 | 2654 | 3410 | 0.7795 | 0.7618 |
MDA-MB-231 | Neratinib | 0.12 | uM | LJP5 | 72 | hr | 868 | 2454 | 3410 | 0.7198 | 0.6929 |
MDA-MB-231 | Neratinib | 0.37 | uM | LJP5 | 72 | hr | 868 | 2194 | 3410 | 0.6441 | 0.6003 |
MDA-MB-231 | Neratinib | 1.11 | uM | LJP5 | 72 | hr | 868 | 1904 | 3410 | 0.5587 | 0.4877 |
MDA-MB-231 | Neratinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 1563 | 3410 | 0.4585 | 0.3445 |
MDA-MB-231 | Neratinib | 10 | uM | LJP5 | 72 | hr | 868 | 715 | 3410 | 0.2099 | -0.0938 |
MDA-MB-231 | JW-7-24-1 | 0.04 | uM | LJP6 | 72 | hr | 868 | 2560 | 3556 | 0.7192 | 0.6985 |
MDA-MB-231 | JW-7-24-1 | 0.12 | uM | LJP6 | 72 | hr | 868 | 2730 | 3556 | 0.7698 | 0.7579 |
MDA-MB-231 | JW-7-24-1 | 0.37 | uM | LJP6 | 72 | hr | 868 | 2426 | 3556 | 0.6821 | 0.6569 |
MDA-MB-231 | JW-7-24-1 | 1.11 | uM | LJP6 | 72 | hr | 868 | 2065 | 3556 | 0.5821 | 0.5322 |
MDA-MB-231 | JW-7-24-1 | 3.33 | uM | LJP6 | 72 | hr | 868 | 1881 | 3556 | 0.5293 | 0.4627 |
MDA-MB-231 | JW-7-24-1 | 10 | uM | LJP6 | 72 | hr | 868 | 876 | 3556 | 0.2466 | 0.0044 |
MDA-MB-231 | Dasatinib | 0.04 | uM | LJP5 | 72 | hr | 868 | 1648 | 3410 | 0.4845 | 0.3843 |
MDA-MB-231 | Dasatinib | 0.04 | uM | LJP6 | 72 | hr | 868 | 777 | 3556 | 0.2184 | -0.0539 |
MDA-MB-231 | Dasatinib | 0.12 | uM | LJP5 | 72 | hr | 868 | 736 | 3410 | 0.2158 | -0.0810 |
MDA-MB-231 | Dasatinib | 0.12 | uM | LJP6 | 72 | hr | 868 | 581 | 3556 | 0.1638 | -0.1805 |
MDA-MB-231 | Dasatinib | 0.37 | uM | LJP5 | 72 | hr | 868 | 496 | 3410 | 0.1457 | -0.2471 |
MDA-MB-231 | Dasatinib | 0.37 | uM | LJP6 | 72 | hr | 868 | 545 | 3556 | 0.1535 | -0.2051 |
MDA-MB-231 | Dasatinib | 1.11 | uM | LJP5 | 72 | hr | 868 | 497 | 3410 | 0.1460 | -0.2459 |
MDA-MB-231 | Dasatinib | 1.11 | uM | LJP6 | 72 | hr | 868 | 508 | 3556 | 0.1429 | -0.2325 |
MDA-MB-231 | Dasatinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 515 | 3410 | 0.1510 | -0.2329 |
MDA-MB-231 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 868 | 460 | 3556 | 0.1292 | -0.2691 |
MDA-MB-231 | Dasatinib | 10 | uM | LJP5 | 72 | hr | 868 | 633 | 3410 | 0.1857 | -0.1489 |